Published in FDA Law Weekly, July 22nd, 2004
There are currently no prescription drugs approved for congenital ichthyosis in the U.S. In prior phase II and phase III clinical trials, oral Liarozole, which represents a new concept in treating this condition, was well tolerated and a majority of patients showed marked improvement in their condition. The drug previously...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.